Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in this procurement [1][2]. Group 1: Company Performance - In the first three quarters of 2025, the sales revenue for Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of total revenue [1]. - Sales revenue for Nifedipine Controlled Release Tablets was 138 million yuan, representing 1.67% of total revenue [1]. - Sales revenue for Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of total revenue [1]. - Sales revenue for Nifedipine Sustained Release Tablets (II) was 108 million yuan, which is 1.30% of total revenue [1]. - Sales revenue for Irbesartan Dispersible Tablets was 79 million yuan, accounting for 0.95% of total revenue [1]. Group 2: Industry Context - The procurement process is expected to stabilize or further reduce prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces risks associated with drug switching due to centralized procurement [2]. - Although the selection may lead to a decrease in overall sales amounts, it is anticipated to solidify existing market shares, with the company likely to enhance its market share due to its brand influence and reliable supply capabilities [2].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 司美格鲁肽 （Semaglutide） 是 诺和诺德 公司开发的一款降糖药物，用于治疗 2 型糖尿病，2021 年 6 月， FDA 批准了司美格鲁肽作为 减肥药 上市 （商品名为Wegovy） 。该药物是一种胰高血糖素样肽-1 （GLP-1） 受体激动剂，能够模拟其作用，减少饥饿感，从而减少饮食、减少热量摄入，因此在减肥方面 效果突出。 除了用于 治疗 2型糖尿病 和 肥胖 ，司美格鲁肽还被发现能够保护心血管健康、降低癌症风 险、帮助戒酒等。 2024 年 10 月， 《 新英格兰医学杂志 》 （NEJM） 发表的临床研究论文显示，司美格鲁肽 能够显著减 轻体重，并显著减轻肥胖相关的 膝关节炎 引起的疼痛 ， 并提高他们参与运动的能力，首次证实了 GLP-1 受体激动剂类新型减肥药物可以治疗骨关节炎。 然而，司美格鲁肽的这种骨关节炎治疗效果，是源于体重减轻导致的关节负荷减少，还是源于其抗炎作 用，亦或是二者兼而有之，目前尚不完全清楚。 2026 年 2 月 9 日， 中国科学院深圳先进技术研究院 童丽萍 研究员、 陈棣 教授、 John R. Speakman 教授及 ...

恒瑞医药公告称，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，注射用 瑞康曲妥珠单抗的药品上市许可申请获受理并纳入优先审评程序。该药品已于2025年5月在国内获批用 于治疗特定肺癌，此次新适应症为治疗经奥沙利铂等治疗失败的HER2阳性结直肠癌成人患者。截至目 前，相关项目累计研发投入约17.73亿元。药品研发上市存在不确定性，公司将及时披露进展。 ...

格隆汇2月10日丨白云山(00874.HK)公布，近日，公司分公司广州白云山医药集团股份有限公司白云山 何济公制药厂("何济公制药厂")收到国家药品监督管理局("国家药监局")签发的《药品补充申请批准通知 书》。 截至公告日，何济公制药厂在口洁喷雾剂研发项目上已投入研发费用合计约人民币 241.36 万元(未审 计)。根据米内网数据显示，2024 年口洁喷雾剂在国内市场的销售额为人民币 5,064 万元。2024 年何济 公制药厂该药品的销售收入为人民币 1,894 万元。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准本品变更药品规格的补充申请。同意将本品规格由"每瓶装 20ml"规范为"每 1ml 相当于饮片 240mg，含薄荷脑 13mg、桉油 2.5μl"。 何济公制药厂于 2025 年 11 月 4 日向国家药监局递交本药品补充申请，申请变更药品规格，于 2025 年 11 月 17 日获得受理。口洁喷雾剂用于口舌生疮，牙龈、咽喉肿痛。 ...

Core Viewpoint - The company, 石四药集团 (Sihuan Pharmaceutical Holdings Group Ltd), is expected to have a positive impact on its business due to the anticipated successful bids for 45 product varieties in the upcoming national centralized procurement in China scheduled for February 10, 2026 [1] Group 1: Product Categories - The 45 product varieties cover multiple therapeutic areas including anti-infection, cardiovascular system, respiratory system, digestive system, and nervous system [1]

Core Insights - The biopharmaceutical ETF (512290) rose over 1% on February 10, with a net inflow of over 500 million yuan in the past 20 days, driven by significant BD and technological advancements [1] Industry Summary - The 2026 JPM Healthcare Conference showcased numerous Chinese pharmaceutical companies presenting their latest research achievements and progress, alongside a surge in large BD deals and active collaborations with multinational corporations (MNCs) [1] - The development of brain-computer interfaces and AI applications is thriving, with consumer-oriented stocks expected to benefit from domestic demand recovery [1] - The industry faces several risks, including geopolitical risks overseas, potential product development failures, increased pricing pressure from expanded centralized procurement, intense competition leading to price declines, and significant rises in raw material costs [1] - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services from the Shanghai and Shenzhen markets to reflect the overall performance of related securities [1]

Group 1 - The core issue is that Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission for violations in annual report disclosures, highlighting significant flaws in the company's financial compliance [1][4] - The company has faced repeated accounting errors, including improper handling of sales returns and insufficient conditions for revenue recognition, leading to restatements of financial data [1][4] - The investigation represents a critical examination of the company's integrity and governance, emphasizing the importance for affected investors to protect their rights within the legal framework [1][4] Group 2 - Nanjing Pharmaceutical has announced a projected annual revenue of 120 million to 150 million yuan for 2025, a decline of approximately 43% to 54% compared to the previous year's revenue of 263 million yuan [2][4] - The company anticipates a net loss of 120 million to 160 million yuan, although this represents a reduction from the previous year's loss of 357 million yuan, indicating ongoing challenges in achieving profitability [2][4] - Factors contributing to the performance decline include intensified competition in the pharmaceutical industry and reduced demand for core products due to a decrease in flu cases, alongside a cautious approach to asset and credit impairment losses [2][5]

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) plans to establish a wholly-owned subsidiary, Zhejiang Yatai Lizhong Investment Holding Co., Ltd., with a capital of 50 million yuan to enhance its industrial development layout [1] Group 1 - The company aims to improve its strategic development and operational planning through this investment [1] - The subsidiary's name is provisional and will be finalized upon approval from the relevant registration authority [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, announced that it is expected to win bids for 45 products in the upcoming national centralized procurement in China, which is anticipated to positively impact its business [1] Group 1: Product Categories - The 45 products cover various therapeutic areas including anti-infection, cardiovascular system, respiratory system, digestive system, and nervous system [1]

Core Viewpoint - Fosun Pharma announced that its subsidiary Shanghai Chaohui Pharmaceutical's registration application for the drug Benzocaine Hydrochloride Gel has been accepted by the National Medical Products Administration. This drug is independently developed by the group for transdermal local anesthesia [1] Group 1: Drug Development and Financials - The drug is expected to have a cumulative R&D investment of approximately 7.19 million yuan by December 2025 [1] - The projected sales revenue for the drug in China is approximately 443 million yuan in 2024 [1] - The commercialization of the drug requires multiple approvals, and the current acceptance does not impact the company's performance at this stage, indicating uncertainty in sales [1]